
Dasatrue 70mg Tablet
Marketer
Cipla Ltd
Salt Composition
Dasatinib (70mg)
Overview Dasatrue 70mg Tablet
Chronic myeloid leukemia (CML) is treated with Dasatrue 70mg tablets. This medication is prescribed for patients whose CML hasn't responded to other treatments or who experience intolerable side effects from alternative therapies. Dasatrue 70mg can be administered with or without food, but consistent daily timing maximizes effectiveness. Dosage and frequency are determined by your physician, based on your specific condition and may be adjusted. Strict adherence to your doctor's instructions is crucial; incorrect usage or overdose may cause severe adverse reactions. Therapeutic benefits might not be apparent for weeks or months; discontinue only under your doctor's guidance. Common side effects include nausea, vomiting, stomach pain, and skin rash. Increased heart rate, and abnormally high or low blood pressure are possible; consult your doctor if these occur. Regular blood pressure monitoring may be necessary. Avoid antacids within two hours of taking Dasatrue. This medication can lower blood cell counts, increasing infection risk; regular blood tests are vital. Inform your healthcare provider of all medications you're taking, as interactions are possible. Dasatrue is contraindicated during pregnancy and breastfeeding. Refrain from driving if dizziness or vision impairment develops.
Uses of Dasatrue 70mg Tablet
Chronic myelogenous leukemia, a type of blood malignancy
Major Benefits of Dasatrue 70mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the 70mg Dasatrue tablet whole; avoid chewing, crushing, or fracturing it. This medication can be taken with or without food, though consistent timing is recommended.
Common Side effects of Dasatrue 70mg Tablet:
- Abdominal pain
- Anemia (low number of red blood cells)
- Breathing problems
- Fatigue
- Fever
- Headache
- Infection
- Low blood platelets
- Musculoskeletal (bone, muscle or joint) pain
- Nausea
- Rash
- Vomiting
How to use Dasatrue 70mg Tablet:
Consume this medication according to your physician's prescribed dosage and schedule. Ingest the tablet whole; avoid crushing, chewing, or fracturing it. Dasatrue 70mg Tablets can be administered with or without food, though consistent timing is recommended.
How Dasatrue 70mg Tablet works:
Oncaspare 70mg tablets are a cancer treatment that inhibits the activity of a faulty protein responsible for cancer cell proliferation, thereby curbing or slowing tumor growth.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
The interaction of alcohol with Dasatrue 70mg Tablet is undefined regarding safety. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Use of Dasatrue 70mg tablets is contraindicated during pregnancy due to established risk to the fetus. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Always seek medical advice.
Breast feedingUNSAFE
Lactation and Dasatrue 70mg tablets are incompatible; evidence indicates potential infant toxicity from this medication.
DrivingUNSAFE
Driving ability may be impaired by Dasatrue 70mg Tablet side effects. Exercise caution while driving if you experience dizziness or blurred vision after taking Dasatrue 70mg Tablet.
KidneySAFE IF PRESCRIBED
The use of Dasatrue 70mg tablets in individuals with kidney disease appears to pose minimal risk. Current evidence indicates dose modification may be unnecessary; however, physician consultation is recommended.
LiverSAFE IF PRESCRIBED
Patients with liver impairment may safely take Dasatrue 70mg tablets without the need for dosage modification.
What if you forget to take Dasatrue 70mg Tablet :
Omit any missed Dasatrue 70mg Tablet dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About Dasatrue 70mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Pyrimidine and Thiazole Derivatives |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Active Class | Kinase inhibitors targeting tyrosine |
